Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,567 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 38,198 · Balance 162,567 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 202,759 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 202,759 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 156,589 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 46,170 · Balance 156,589 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 194,786 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 15, 2021 01:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 2,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008948 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,566 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,825 | $36.53 | $103,197.25 |
DisclosureSEC source: 0001437749-21-008330 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,204 F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 7,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008330 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 26, 2021 Filed Mar 31, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,120 | $35.01 | $74,221.20 |
DisclosureSEC source: 0001437749-21-007717 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,750 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,565 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $36.72 | $226,195.20 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.45 to $37.00 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,725 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $36.91 | $227,365.60 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $37.50 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,876 | $40.76 | $76,465.76 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,870 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,882 | $40.67 | $76,540.94 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,746 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,842 | $41.55 | $76,535.10 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,628 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,885 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,164 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,045 Underlying: Common Stock · 6,164 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,160 | $44.25 | $272,580.00 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.73 to $44.8 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,164 | $44.70 | $275,530.80 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.68 to $45.5 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,164 | $1.64 | $10,108.96 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 3,610 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,610 Underlying: Common Stock · 3,610 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 3,610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,488 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 02:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-024049 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 05/04/2016, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 06/04/2016. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 02:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,000 | $32.16 | $160,800.00 |
DisclosureSEC source: 0001437749-20-024049 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.78 to $32.30, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 02:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 5,000 | $2.06 | $10,300.00 |
DisclosureSEC source: 0001437749-20-024049 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-024049 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 05/04/2016, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 06/04/2016. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,000 | $32.46 | $194,760.00 |
DisclosureSEC source: 0001437749-20-024049 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.40 to $32.54, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 02:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,000 | $2.06 | $12,360.00 |
DisclosureSEC source: 0001437749-20-024049 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 01:41 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 808 | $28.63 | $23,133.04 |
DisclosureSEC source: 0001437749-20-020644 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 9,641 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006396 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,641 Underlying: Common Stock · 9,641 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 16,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006396 · rdgdoc.xml · derivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,068 Underlying: Common Stock · 16,068 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 16,068 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006396 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,686 F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 3,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006396 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,618 F2 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F2 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 3,616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006396 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,690 F1 · security: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. F1 · price: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-024628 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $15.68 | $47,040.00 |
DisclosureSEC source: 0001437749-19-024628 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.64 to $15.70 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-024628 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-022981 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · V.P. Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $14.06 | $42,180.00 |
DisclosureSEC source: 0001437749-19-022981 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · V.P. Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.10 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-022981 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · V.P. Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 18, 2019 01:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-020229 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| October 15, 2019 Filed Oct 18, 2019 01:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $16.06 | $48,180.00 |
DisclosureSEC source: 0001437749-19-020229 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.06 to $16.07 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2019 Filed Oct 18, 2019 01:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-020229 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2019 Filed Sep 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-018656 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| September 16, 2019 Filed Sep 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $20.02 | $60,060.00 |
DisclosureSEC source: 0001437749-19-018656 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.19 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2019 Filed Sep 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-018656 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-017141 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $17.97 | $53,910.00 |
DisclosureSEC source: 0001437749-19-017141 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.01 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-017141 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2019 Filed Jul 18, 2019 00:16 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-014176 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.